Amit Verma, MD, Guillermo Garcia-Manero, MD, and Rami Komrokji, MD
In this episode, “New Frontiers in MDS,” Amit Verma, MD, Guillermo Garcia-Manero, MD and Rami Komrokji, MD discuss emerging concepts in MDS management.
Extensive scientific research has better elucidated the biology underlying myelodysplastic syndromes (MDS), including the roles of somatic mutations and inflammation. It is anticipated that standard practices will soon adopt biology-directed diagnosis, prognosis and treatment. Indeed, some agents in development (e.g., luspatercept) have the potential to impact the biology and course of disease.